Ensoma Announces Clearance of U.K. Clinical Trial Authorization Application for EN-374, First In Vivo HSC-Directed Gene Insertion Therapy MHRA authorization to initiate Phase 1/2 clinical trial at U.K ...
Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced U.K. Medicines and Healthcare Products Regulatory Agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback